Corrigendum: Anlotinib Combined With Anti-PD-1 Antibodies Therapy in Patients With Advanced Refractory Solid Tumors: A Single-Center, Observational, Prospective Study
Keyword(s):
2019 ◽
Vol 234
◽
pp. e174-e175
Keyword(s):
Keyword(s):
Keyword(s):
Keyword(s):